F045 Granulomatous Disorders of the Adult Skin
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
*PLEASE MASK-UP: Masking requested for this session*
Granulomatous disorders represent a unique group of diseases, both noninfectious and infectious, that require clinical pathological correlation combined with a keen sense of inquiry for underlying systemic disease and pharmacologic utilization. Dermatologists need to be able to differentiate granuloma annulare, sarcoidosis, necrobiosis lipoidica, reactive granulomatous dermatitis and drug-induced granulomatous reactions, evaluate patients for underlying systemic diseases, and treat them with appropriate therapeutic agents. By being aware of the skin manifestations of these abnormal physiologic responses from underlying disease or medication usage dermatologists can improve patient safety, outcome and health care costs.
LEARNING OBJECTIVES
Review granulomatous diseases of the skin, providing a framework to recognize different clinical presentations, interpret dermatopathology, evaluate patients for systemic disease involvement, and develop an approach to treatment
Identify characteristics of and differentiate between Granuloma Annulare, Necrobiosis Lipoidica, Sarcoidosis, Reactive Granulomatous Diseases (IGD/PNGD), Necrobiotic Xanthogranuloma, Cutaneous Crohn Disease, and more
SCHEDULE
5:00 PM
Introduction
Misha Rosenbach, MD, FAAD
5:05 PM
Granuloma Annulare
Juliana P Berk-Krauss, MD, FAAD
5:15 PM
Sarcoidosis
Avrom Caplan, MD, FAAD
5:25 PM
Orofacial Granulomatosis/Granulomatous Cheilitis
Alexandra Coromilas, MD, FAAD
5:35 PM
Crohn / Inflammatory Bowel Disease
Bridget Shields, MD, FAAD
5:45 PM
Necrobiosis Lipoidica / Clinical Trials
Aaron Mangold, MD, FAAD
6:15 PM
Necrobiotic Xanthogranuloma
Caroline Nelson, MD, FAAD
6:30 PM
Granulomatous Dermatitis in Immunodeficiency
Karolyn Wanat, MD, FAAD
6:45 PM
JAK inhibitors and Granulomatous Diseases
William Damsky, PhD, MD, FAAD
6:55 PM
Cases & Closing
SPEAKERS
Juliana P Berk-Krauss, MD, FAAD
Avrom Caplan, MD, FAAD
Alexandra Coromilas, MD, FAAD
William Damsky, PhD, MD, FAAD
Aaron Mangold, MD, FAAD
Caroline Nelson, MD, FAAD
Misha Rosenbach, MD, FAAD
Bridget Shields, MD, FAAD
Karolyn Wanat, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Juliana P Berk-Krauss, MD, FAAD
No financial relationships exist with ineligible companies.
Avrom Caplan, MD, FAAD
No financial relationships exist with ineligible companies.
Alexandra Coromilas, MD, FAAD
No financial relationships exist with ineligible companies.
William Damsky, PhD, MD, FAAD
AbbVie – Investigator(Fees); Advanced Cell Diagnostics, Inc. – Investigator(Equipment); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); CSL Behring – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Fees); Epiarx Diagnostics – Consultant (1099 relationship)(Fees); Fresenius Kabi – Consultant (1099 relationship)(Fees); Incite – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); MilliporeSigma – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); TWi Biote – Consultant (1099 relationship)(Fees); TWi Biotechnology, Inc. – Consultant(Fees), Consultant (1099 relationship)(Fees), Investigator(Fees);
Aaron Mangold, MD, FAAD
arGEN-X – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria); clarivate – Consultant(Grants/Research Funding); Corbus Pharmaceuticals – Investigator(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Janssen Global Services, LLC – Consultant(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria); Kyowa Kirin – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); miRagen Therapeutics, Inc. – Investigator(Grants/Research Funding); Momenta Pharmaceuticals, Inc. – Advisory Board(Honoraria); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); PHLECS – Advisory Board(Honoraria); Priovant – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Solgenix, Inc. – Investigator(Grants/Research Funding);
Caroline Nelson, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Misha Rosenbach, MD, FAAD
J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); Novartis – Consultant(Honoraria);
Bridget Shields, MD, FAAD
No financial relationships exist with ineligible companies.
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.